SCHEMBL21611934

SCHEMBL21611934

FC(F)(F)c1cc(SCc2nc3ccc(Oc4ccccc4)cc3o2)ccn1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ SLC27A1 Q6PCB7 3/20 0.36
▸ LOX P28300 1/20 0.35
▸ LOXL2 Q9Y4K0 1/20 0.35
▸ PDE10A Q9Y233 3/20 0.35
▸ BLM P54132 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.33
▸ SDHB P21912 1/20 0.33
▸ ACSS2 Q9NR19 1/20 0.33
▸ GCK P35557 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2E1 P05181 1/20 0.32
▸ CYP2C8 P10632 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2B6 P20813 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21611971 0.82 CYP3A4 (0.39) CYP3A4CYP2C19LOXLOXL2BLM
SCHEMBL30040466 0.82 SLC27A1 (0.39) SLC27A1
SCHEMBL25401962 0.82 SLC27A1 (0.39) SLC27A1
SCHEMBL21611993 0.80 CYP2C19 (0.54) CYP3A4CYP2C19SLC27A1LOXLOXL2
SCHEMBL21611941 0.77 CACNA1H (0.37) CYP3A4CYP2C19LOXLOXL2PDE10A
SCHEMBL21611983 0.76 PDE10A (0.48) CYP3A4CYP2C19LOXLOXL2PDE10A
SCHEMBL21611943 0.75 CYP3A4 (0.41) CYP3A4CYP2C19
SCHEMBL21611925 0.73 CYP3A4 (0.41) CYP3A4CYP2C19LOXLOXL2PDE10A
SCHEMBL21612047 0.73 PPARD (0.48) CYP3A4CYP2C19LOXLOXL2PDE10A
SCHEMBL30763500 0.72 F2 (0.37) CYP3A4CYP2C19PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11883387-B2 PqsR inverse agonists Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2024-01-30 — — US disclosed
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11883387-B2 PqsR inverse agonists QRFPR, P2RY11, QARS1 CYP3A4 3080/4885CYP2C19 1824/4885SLC27A1 2329/4885
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 CYP3A4 3080/4885CYP2C19 1824/4885SLC27A1 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback